Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the bioavailability and pharmacokinetics (PK) of
multiple doses of vedolizumab subcutaneous (SC) compared to vedolizumab intravenous (IV).